Onbrez Breezhaler (Indacaterol)

Indacaterol, the active ingredient in Onbrez Breezhaler, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhalation formulation for inhalation use. It provides bronchodilation for adults with chronic obstructive pulmonary disease (COPD). GNH USA supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Onbrez Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Onbrez Breezhaler contains indacaterol, a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in chronic lung disease. - Chronic obstructive pulmonary disease (COPD): provides once‑daily maintenance bronchodilation and reduces exacerbation risk. - Stable COPD with dyspnoea: improves exercise tolerance and health‑related quality of life. - COPD patients inadequately controlled on short‑acting bronchodilators: offers a long‑acting alternative for symptom control.

Adverse reactions to indacaterol are reported across a range of frequencies.

Common Side Effects: - Cough - Throat irritation - Nasopharyngitis - Headache - Dry mouth - Upper respiratory tract infection

Serious or Rare Side Effects: - Paradoxical bronchospasm - Cardiovascular events such as tachycardia or palpitations - Severe allergic reactions (anaphylaxis) - Hypersensitivity skin reactions - Acute COPD exacerbation - Pneumonia

When using Onbrez Breezhaler, consider the following safety measures: - Assess patient history: review    - Monitor   - Counsel   - Avoid use   - Store at ambient :   -  

Indole      

Major  

   t